Why We Need Biomarkers in Psychiatry - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Why We Need Biomarkers in Psychiatry

Consensus statement outlines how standardized, validated biological tests could move psychiatric diagnosis and treatment beyond symptom-based classification

  • September 30, 2026

  • 2 min

Share

  • 1

    The ACNP emphasizes the need for standardization and collaboration in psychiatric biomarker development for clinical utility.

  • 2

    Few psychiatric biomarkers have advanced beyond exploratory research, with trials focusing on symptoms rather than biological mechanisms.

  • 3

    The proposed roadmap includes a framework for validating biomarkers through various methods, including blood assays and neuroimaging.

  • 4

    Analytical validation is crucial, requiring reliable measurement of targets and established performance characteristics before clinical application.

  • 5

    Near-term applications of biomarkers aim to enhance clinical trials and treatment monitoring, while long-term goals focus on precise patient subgroup identification.

Original Source(s)

Why We Need Biomarkers in Psychiatry

  • September 30, 2026

Related Content

Two General Sessions, One Reason to Be in Montréal

What to expect at the ASCP Annual Meeting 2026

The Colorimetric Scale for Skin of Color (CSSC) can Provide a Standardized Classification System for Patients with Diverse Skin Tones

GC×GC Detective Stories: Biomarkers, Biofuels, and Shape-Shifting Molecules

Philip Marriott, Renée Webster, and Konstantinos Kouremenos revisit three investigations in which an additional dimension of separation provided the information needed to solve three very different analytical mysteries